Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M. Verónica Lopez"'
Autor:
M Verónica Lopez, Diego L Viale, Eduardo G A Cafferata, Alicia I Bravo, Cecilia Carbone, David Gould, Yuti Chernajovsky, Osvaldo L Podhajcer
Publikováno v:
PLoS ONE, Vol 4, Iss 4, p e5119 (2009)
The clinical efficacy of conditionally replicative oncolytic adenoviruses (CRAd) is still limited by the inefficient infection of the tumor mass. Since tumor growth is essentially the result of a continuous cross-talk between malignant and tumor-asso
Externí odkaz:
https://doaj.org/article/d79f19cd56fc43ba8289f110672aec01
Publikováno v:
The Journal of Immunology. 175:5885-5894
Preclinical studies demonstrated that certain cytokines are potentially useful for the induction of antitumor immune responses. However, their administration in clinical settings was only marginally useful and evoked serious toxicity. In this study,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce651e244f6b3c86673315d15379e254
https://doi.org/10.4049/jimmunol.175.9.5885
https://doi.org/10.4049/jimmunol.175.9.5885
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M. Verónica López, Sabrina E. Vinzón, Eduardo G. A. Cafferata, Felipe J. Núñez, Ariadna Soto, Maximiliano Sanchez-Lamas, M. Jimena Afonso, Diana Aguilar-Cortes, Gregorio D. Ríos, Juliana T. Maricato, Carla T. Braconi, Vanessa B. Silveira, Tatiane M. Andrad, Tatiana C. S. Bonetti, Luiz M. Ramos Janini, Manoel J. B. C. Girão, Andrea S. Llera, Karina A. Gomez, Hugo H. Ortega, Paula M. Berguer, Osvaldo L. Podhajcer
Publikováno v:
Vaccines, Vol 9, Iss 10, p 1106 (2021)
Most approved vaccines against COVID-19 have to be administered in a prime/boost regimen. We engineered a novel vaccine based on a chimeric human adenovirus 5 (hAdV5) vector. The vaccine (named CoroVaxG.3) is based on three pillars: (i) high expressi
Externí odkaz:
https://doaj.org/article/b0086f266e2e4a949a588004e905c559
Autor:
Ana Laura Alfano, Alejandro Nicola Candia, Nicasio Cuneo, Leandro N. Guttlein, Alejandro Soderini, Cecilia Rotondaro, Leonardo Sganga, Osvaldo L. Podhajcer, M. Veronica Lopez
Publikováno v:
Molecular Therapy: Oncolytics, Vol 6, Iss C, Pp 31-44 (2017)
Patients with ovarian cancer present peritoneal ascites at recurrence as a marker of disseminated disease and dismal prognosis. Oncolytic immunotherapy is an emerging approach for the treatment of disseminated cancer. In the present work, we construc
Externí odkaz:
https://doaj.org/article/fc689fe1e5fb4854ab3ba7442bb28c4b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.